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Abstract
Genome-wide association studies (GWASs) assess correlation between traits and DNA sequence variation using large
numbers of genetic variants such as single nucleotide polymorphisms (SNPs) distributed across the genome. A GWAS
produces many trait-SNP associations with low p-values, but few are replicated in subsequent studies. We sought to
determine if characteristics of the genomic loci associated with a trait could be used to identify initial associations with a
higher chance of replication in a second cohort. Data from the age-related eye disease study (AREDS) of 100,000 SNPs on
395 subjects with and 198 without age-related macular degeneration (AMD) were employed. Loci highly associated with
AMD were characterized based on the distribution of genotypes, level of significance, and clustering of adjacent SNPs also
associated with AMD suggesting linkage disequilibrium or multiple effects. Forty nine loci were highly associated with AMD,
including 3 loci (CFH, C2/BF, LOC387715/HTRA1) already known to contain important genetic risks for AMD. One additional
locus (C3) reported during the course of this study was identified and replicated in an additional study group. Tag-SNPs and
haplotypes for each locus were evaluated for association with AMD in additional cohorts to account for population
differences between discovery and replication subjects, but no additional clearly significant associations were identified.
Relying on a significant genotype tests using a log-additive model would have excluded 57% of the non-replicated and
none of the replicated loci, while use of other SNP features and clustering might have missed true associations.
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Introduction
Genetic variation altering the risk of developing common and
complex traits or diseases is being discovered using genome wide
association studies (GWASs) [1]. Genetic association studies
typically seek to identify common sequence variation indirectly
associated with a trait. Replication, detailed genotyping, and
functional studies subsequently determine which of the variations
in a given locus are most likely to be directly associated with
disease and which are inherited along with other variants in the
population (linkage disequilibrium).
Although a GWAS is a powerful means for discovering trait-
associated variants [2], a large number of variants are typically
identified with small p-values suggestive of possible association. Most
of these variants (e.g., single nucleotide polymorphisms, SNPs) are
not associatedwithdisease insubsequent replicationstudies[3], even
with well-designed studies using a larger number of subjects. The
large numberofSNPs(say 100,000 or more) studied means that with
a liberal P-value of 0.001, approximately 100 SNPs would be
associated with the trait by chance alone. In addition to association
by chance alone, other reasons for spurious association include
population stratification and genotyping artifacts [4]. Thus, a major
challenge in replication of GWASs is how to define a significant
association using p-values or other features.
A number of strategies have been proposed to identify the SNPs
more likely to be truly associated with the trait [4,5]. It is generally
accepted that methods (e.g., the Bonferroni correction) based on
the number of tests (e.g., SNPs) are overly conservative because the
tests are not independent as a result of linkage disequilibrium.
Because multiple loci in the genome are being sought in a GWAS,
estimates incorporating the prior odds of association and the
power to detect association have been proposed [6] and others
have discussed the advantages of non-parametric tests based on
genotype counts or multilocus modeling [7–9]. A commonly
employed empirical method is the quantile-quantile plot, where
the values of the observed test statistics are plotted against the
expected observations [5]. Deviation from the expected suggests
the range of potentially significant observations.
Generally SNPs without common minor alleles and accurate
genotype call rates are excluded from subsequent analysis, because
SNPs without these features are more likely to represent artifacts
[4]. It is commonly thought that clustering of SNPs associated with
the trait within a chromosomal region excludes genotyping error
and may identify regions more likely to harbor disease associated
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loci for replication, an essential component of all GWASs is
replication in additional, independent cohorts, preferably with
larger sample sizes [3].
In this study, we sought first to test the idea that features of
individual SNPs associated with disease and clustering of nearby
significant SNPs (i.e., support for association from adjacent SNPs)
would be useful in selecting loci from genetic association studies for
replication [4]. We hypothesized that true disease-associated SNPs
would have genotype distributions that fit a log-additive model as
well or better than two degree of freedom x
2 tests and would be
more likely to have nearby SNPs also associated with disease (due
to linkage disequilibrium). The log-additive model is less sensitive
to changes driven only by differences in heterozygote frequencies
between cases and controls and thus is impacted less by this
common effect of genotyping error or population stratification
[10]. We also explored the possibility that failure to replicate
individual SNPs could arise due to differences in the structure of
linkage disequilibrium between discovery and replication subject
groups as has been suggested by some investigators [11]. To
address these questions we attempted to replicate disease-
associated SNPs from a recently released and publically
available GWAS through dbGaP ((http://view.ncbi.nlm.nih.gov/
dbgap-controlled), accession number phs000001.v1.p1.) on subjects
with age-related macular degeneration (AMD; OMIM 603075).
AMD is a common trait with well established genetic risks. By
the year 2020, three million people in the United States are
expected to have advanced AMD that often leads to severe vision
loss [12]. AMD is inherited as a complex trait arising from genetic
risks, environmental factors such as smoking, lifestyle and body
habitus, and diet/nutritional status [13]. Numerous genomic loci
have been identified with replicated association with AMD, as
recently reviewed by Edwards and Malek [14]. The regulation of
complement activation (RCA) locus contains multiple haplotypes
altering AMD risk including the haplotype carrying the Y402H
variation in complement factor H (CFH; Gene ID 3075) [15–18].
Protective variants in the complement pathway were subsequently
identified in the complement component 2/B factor (C2/BF; Gene
IDs 712/629) locus [19]. Recently, two reports of association with
variation in the complement component 3 (C3; Gene ID 718) locus
were published [20,21]. The chromosome 10q26 region, spanning
the hypothetical gene LOC387715 (Gene ID 387715) and the
beginning of the HTRA1 (Gene ID 5654) gene was the second
major locus identified [22–25]. Thus, there is strong evidence for
the involvement of the innate immune system and at least one
other pathway in the pathogenesis of AMD.
The age-related eye disease study (AREDS) was a multi-
centered clinical trial, which demonstrated the protective effect of
antioxidants and zinc on preventing the exudative complications
of AMD [26]. Subjects from this study were used in the most
powered GWAS on AMD reported to date and is an appropriate
dataset for the present investigation, given the clearly established
role of heredity for this disease. These data from 100,000 SNPs on
395 AMD cases and 198 controls without AMD were recently
deposited into dbGaP. During the preparation of this manuscript a
replication study using discordant sib-pairs was reported [27].
Herein, we report that the AREDS GWAS identified the loci
already known at the time the data was deposited into dbGaP,
namely the CFH, LOC387715/HTRA1, and C2/BF loci. Of the
57 other loci associated with AMD (P,10
24), one additional locus
(C3) reported during the course of this study [20,21] was replicated
in this study based on highly significant association tests and
genotyping with independent technologies in multiple cohorts. All
replicated loci were highly significant with the log-additive model,
but so were many of the non-replicated loci. Support from
adjacent SNP arose secondary to linkage disequilibrium in both
replicated and non-replicated loci and was not a useful
discriminator. Genotyping of tag-SNPs provided support for failed
replication, but did not identify any additional clearly replicated
loci in this study.
Materials and Methods
Subjects
The AREDS subjects genotyped by the AREDS investigators
on the Illumina 100,000 SNP platform consisted of 593 individuals
(395 AMD cases, 198 controls). These subjects were recorded as
non-Hispanic white (97.6%), non-Hispanic black (2%), Hispanic
(0%), Asian or pacific islander (0%), or other (0.34%). Access to
the raw data from the AREDS trial was provided via the National
Eye Institute. Replication of loci identified in the AREDS GWAS
on the Mayo subjects used 744 individuals (444 AMD cases, 300
controls without AMD). The use of these subjects was approved by
the institutional review board of the Mayo Clinic, written consent
was obtained from all subjects and the study was performed in
accordance with the Helsinki declaration. Diagnosis was deter-
mined by review of fundus photographs as previously described
[15]. Briefly, all subjects diagnosed with AMD had large drusen or
more advanced findings and controls had 5 or fewer hard drusen
without pigment changes or more advanced findings. Replication
of tag- or ns-SNPs associated with AMD in the Mayo subjects was
performed on DNA samples from AREDS subjects (1,280 cases,
318 controls without AMD). The AREDS DNA samples were
provided by the AREDS Operations Committee. Controls
included AREDS control categories control, and control ques-
tionable groups 1–4, and AMD cases included AMD categories
NV AMD, GA, Both, Large Drusen, Large Drusen Questionable
groups 1–3, and Questionable advanced AMD.
Selection of loci from the AREDS dataset for replication
Results of 262 allelic tests publically available on dbGaP were
used to select SNPs for further study. SNPs with an uncorrected p-
value less than 10
24 might represent a significant association with
disease and this threshold for replication was employed. Individual
genotype counts were not available until late in this study due to
the time required to gain access to the dataset and thus were not
available initially to perform statistical analyses. Therefore, we
reviewed the allele association data for all SNPs with p-values less
than 0.0001. The allele frequencies of the 100,000 SNPs were
reviewed along with the P-values for association with AMD,
Hardy-Weinberg equilibrium (HWE), and support from adjacent
SNPs. An attempt was made to replicate all SNPs associated with
AMD, except those in the artifact groups (see Table 1 for
explanation). The definition of a locus for this project is provided
in the footnotes to Table 1.
Selection of tag and functional SNPs
Non-synonymous SNPs within 50 kb of a significant SNP in the
AREDS study (p-value less than 0.0001) were genotyped. Tag-
SNPs were selected by inspecting the genomic region of each
replicated locus for genes within 20 kb or within an LD block of
any SNP associated with AMD. Caucasian data from HapMap in
the genomic region of each gene and 2 kb upstream and
downstream were used for selecting tag-SNPs. Illumina genotyp-
ing scores were obtained for SNPs within the selected genomic
regions. SNPs with a score greater than 0.6 were used for further
analyses. After merging the files containing Illumina scores with
the list of candidate tag-SNPs generated using ldSelect [28] with
GWAS Replication
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2 of at least 0.8, an
algorithm for tag-SNP selection was developed so that a single tag-
SNP would be selected for each LD bin. This algorithm was
applied using SAS Version 8.02 (Cary, NC). Only those SNPs
deemed candidate tag-SNPs by ldSelect with an Illumina score
greater than or equal to 0.60 and a MAF of greater than or equal
to 0.05 were considered for further selection using this algorithm.
Tag-SNPs were ultimately selected based upon a functional
ranking system wherein non-synonymous coding SNPs were
preferentially selected among the tag-SNP candidates in each
LD bin, followed by synonymous coding SNPs, SNPs from 59
untranslated regions (UTRs), SNPs from 39 UTRs, SNPs from 59
flanking UTRs, SNPs from 39 flanking UTRs, and finally SNPs
from intronic regions. If an LD bin contained more than one tag-
SNP with the same highest function ranking, the SNP with the
highest MAF was selected as the tag for that bin. This algorithm
was applied to tag-SNPs from the confirmed, confirmed rare,
valid, and valid rare categories (Table 1). All other non-
synonymous SNPs with Illumina scores greater than or equal to
0.60 and MAFs greater than or equal to 0.05, as well as the
significant SNPs from the AREDS dataset, were added to the list
of tag-SNPs for each category. LD bins containing only one SNP
(referred to hereafter as a ‘‘singleton SNP’’) were excluded from
further analysis. Using the list of SNPs generated from the
algorithm described above, gene coverage maps were then
produced using R 2.5.0 to visually assess the degree of coverage
provided by the tag-SNPs that had been selected, as well as their
proximity to the significant SNPs from the AREDS dataset. For
large genes with adequate coverage but more than 10 LD bins,
only tag-SNPs with LD bins within 10 kb of a significant AREDS
SNP were selected for genotyping. For genes with low overall
coverage or with tag-SNPs in low proximity to a significant
AREDS SNP, additional SNPs were selected from these genes if
they were located 1–2 kb upstream or downstream of a significant
AREDS SNP and had Illumina scores and MAFs greater than or
equal to 0.6 and 0.05, respectively. A final list of tag-SNPs, non-
synonymous SNPs, and significant AREDS SNPs was then
compiled and examined to ensure that no two SNPs were within
60 bp of each other. SNPs for which this was true were excluded.
The resulting SNPs were genotyped as described below.
Genotyping
We designed an Illumina GoldenGate
TM assay for these 243
SNPs such that ninety three percent of the SNPs had Illumina
SNP scores .0.6. Genomic DNA samples (250 ng) were
genotyped following the Illumina protocol (Illumina, San Diego,
CA). Genotype calls were made using the Genotyping module of
the BeadStudio 3 software. Genotype clusters were reviewed using
the replicate and heritability information of 16 control CEPH trios
to refine clustering. Initial laboratory quality assurance relied on
the GenCall score, a quality metric indicating the reliability of
called genotypes that is generated by the BeadStudio software.
The GenCall_10 refers to the 10th percentile GenCall score in a
particular distribution of GenCall scores. For loci, it represents the
10th percentile rank for all GenCall scores for that locus. Samples
with GenCall_10 scores below 0.4 and/or call rates below 90%
and SNPs with call rates below 90% were failed. Quality control
for genotype call was assessed by concordance for the control
CEPH trio DNA replicates and the sample replicates within each
plate (2 per 96 well plate).
Statistics
Upon receipt of genotype intensities, all SNPs were validated by
reviewing the accuracy of genotype discrimination (clustering)
methods. SNPs or subjects with call rates lower than 95% or not in
Hardy-Weinberg equilibrium (P,0.001) were excluded from
further analyses. Any SNP presented in tables in the main
manuscript have HWE p-values of 0.05 or higher in controls,
unless pointed out in the text. Single SNP analyses on genotype
distributions [10], were performed in SAS version 8 (SAS Institute;
Cary, NC) using logistic regression assuming a log-additive model
where SNPs were coded as 0, 1, or 2 for the number of minor
alleles. Fisher’s exact tests were also performed on genotype
distributions. Intragenic haplotype tests were completed using the
score test with a 3 SNP sliding window approach within each gene,
as implemented in haplo.stats [29].
Table 1. Number of loci with at least one SNP significantly associated with AMD in the 100,000 SNP genome-wide scan of the
AREDS cohort*.
Group
Hardy-Weinberg
equilibrium (HWE)
in controls (P$0.01)
Minor allele
frequency.1%
in cases or controls
One or more
adjacent SNPs
associated with AMD**
Number of
loci***
Total SNPs
with P,10
24
Confirmed Yes Both Yes 20 30
Confirmed-Rare Yes Either Yes 6 8
Valid Yes Both No 14 14
Valid-Rare Yes Either No 6 6
Sub-total 46 58****
Loci already associated with AMD Yes Either Yes 3 25
Artifact - Possible No NA No 20 23
Artifact - Probable No Either or Both Yes 30 65
Total 99 171
*Significant association was defined as P,10
24.
**An adjacent SNP associated with AMD refers to the nearest centromeric and telomeric SNP within 50 kb or less genotyped on the Illumina 100,000 SNP genome-wide
scan with a p-value#0.01 for association with AMD. SNPs meeting this criteria are referred to as ‘‘confirmed’’.
***SNPs associated with AMD were arbitrarily defined as being in separate loci if they were located at least 500 kb from each other.
****One of these 58 SNPs (rs7497988, now called rs3985626) could not be genotyped on the Illumina platform and was not studied. The already known and artifact
categories were not genotyped, leaving 57 AREDS SNPs in 46 loci.
doi:10.1371/journal.pone.0003813.t001
GWAS Replication
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Loci associated with AMD in the AREDS subjects
Allelic p-values (262 x
2) were publically available on dbGaP at the
time this study was initiated and these statistical tests were used to
select SNPs for replication. Table 1 presents the number of loci with
allelic p-values of less than 10
24 that were identified. Inspection of the
loci suggested that they could be characterized based on clustering
(support from adjacent SNPs for association with AMD), Hardy-
Weinbergequilibrium(HWE),andminorallelefrequency.Fortynine
loci were highly associated with AMD and had features suggestive of
valid genotyping results (confirmed and valid categories in Table 1).
Of these 49 loci, there were 46 not already known to be associated
with AMD containing a total of 58 SNPs showing association with
AMD (p,10
24). One AREDS SNP (rs7497988, now called
rs3985626) could not be genotyped on the Illumina platform, leaving
57 AREDS SNPs that were studied. Three tag-SNPs (rs12907196,
rs12899318, and rs12442417) were studied in place of rs3895626.
The details of these 57 AREDS SNPs are presented in Table S1,
including analysis of raw genotype data that became available late
during the course of this study. Notably, the three loci already known
to be associated with AMD (CFH, LOC387715/HTRA1,a n dC2/BF)
a tt h et i m eo ft h er e l e a s eo ft h eA R E D SG W A Sw e r ea s s o c i a t e dw i t h
AMD. Loci from the X chromosome were excluded, because the
hemizygous males were not analyzed separately from females by
dbGaP and the association analysis could not be interpreted from the
dbGaP data at the start of the study.
Replication of AREDS SNPs highly associated with AMD in
the Mayo subjects
Replication of these 57 SNPs was attempted using the Illumina
platform and a larger group of subjects consisting of 444 subjects
with AMD and 300 subjects without AMD, hereafter referred to as
the Mayo subjects. Only one (rs2230199; C3) of the 57 AREDS
SNPs was clearly replicated in the Mayo subjects (Table 2). Four
other AREDS SNPs showed a trend toward association with AMD
with an additive p-value of less than 0.01 (Table 2). Four SNPs failed
on the Illumina platform and the one SNP (rs10920091) with minor
allele frequency above 5% was genotyped using Taqman and was
not associated with AMD. A summary of the biological features and
the statistical tests for genotype distributions for these 57 SNPs in the
AREDS and Mayo subjects is presented in Table S2. Genotype
counts for all SNPs in this study are provided in Table S3.
Detailed study of tag-SNPs and non-synonymous coding
SNPs across the AREDS loci in the Mayo subjects
The AREDS study was a multi-centered clinical trial based in the
USA without strict racial or ethnic enrollment criteria [26], raising
the concernthat population substructure might existwithinthestudy
subjects. Because of the concern that individual SNPs might not
replicate between the AREDS subjects and the Mayosubjects due to
differences in linkage disequilibrium, tag-SNP and functional-SNP
approaches were used to look for association in the 46 loci. The tag-
SNPs were selected using linkage disequilibrium as detailed in the
methods section. An additional 225 tag-SNPs and 18 non-
synonymous SNPs (nsSNPs) were genotyped in the Mayo subjects.
Three of the four loci (5 tag-SNPs) showed a trend toward
association with AMD using log-additive modeling (Table 3).
Genotyping of AREDS subjects locally for the tag-SNPs
associated with AMD in the Mayo subjects
The 3 loci that were possibly associated with AMD in the Mayo
subjects by genotyping of tag-SNPs (Table 3) were studied using
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genotyped on 1280 cases and 318 controls from the AREDS trial
(Table 4). Note that the 593 AREDSsubjects that were genotyped in
100,000 SNP GWAS (unpublished) deposited in dbGaP overlap
partially with the 1598 AREDS subjects genotyped in our
laboratory. One of these SNPs was marginally associated with
AMD (Table 4), but was not in HWE (P=0.000026). Additional
studies are needed to understand if this SNP alters the risk of AMD.
Variables associated with replication using genotype
data from the disease-associated SNP and nearby SNPs
(clustering)
The results presented above demonstrate that 4 of 49 AREDS
loci associated with AMD in the 100,000 SNP GWAS were clearly
associated with AMD by replication in an independent group of
subjects. Although the number of already known (3 loci) and
replicated loci (1) was not large enough to build a predictive
model, we inspected the features of both groups of AREDS SNPs
(replicated and non-replicated) for insights that might facilitate
efficient selection of SNPs for replication (Table S1 and Table 5).
Clustering of SNPs associated with AMD was present in both
replicated and non-replicated loci. Indeed, except for the
regulation of complement activation locus where an extensive
linkage disequilibrium block contains CFH and related genes [15],
the clustering ranged from 0–2 for both groups of AREDS SNPs.
The clustering arose secondary to linkage disequilibrium in both
replicated and non-replicated loci based on data from HapMap
(www.hapmap.org). We have found the log-additive model for
genotype distribution a useful parameter in identifying SNPs that
are not truly associated with disease in recent projects [30].
Nonetheless, 60% of non-replicated SNPs had p-values from a log-
additive genetic model (1 degree of freedom trend test) more
significantly associated with disease than by analyses assuming no
genetic mdoel (2 degree of freedom x
2 analysis). Other features
such as level of significance (p-values) and minor allele frequency
were not useful discriminators in this dataset (Table S1).
Discussion
We identified 49 loci in the AREDS 100,000 SNP GWAS that
were associated with AMD (P,10
24). Three of these 49 loci were
already known to be associated with AMD and the SNPs meeting
our replication criteria (Table 1) from the remaining 46 loci were
genotyped in a second, independent group of subjects with and
without AMD from the Mayo Clinic. One SNP from these loci in
the C3 gene showed association with AMD, while the remaining
56 SNPs did not show clear evidence for association. The SNP in
C3 (rs2230199) has been replicated recently in other studies, while
this project was ongoing [20,21].
The observation that C3 coding polymorphisms are highly
associated with AMD in multiple groups of subjects provides
further support for the involvement of the alternative pathway of
complement in the pathogenesis of AMD. The Arg80Gly
(rs223019) polymorphism corresponds to the electrophoretically
slow (Arg) and fast (Gly) forms of C3 and may be the causative
Table 3. Attempted replication of AREDS loci using 225 Tag-SNPs and 18 nsSNPs genotyped on the Mayo subjects.
Chromosome AREDS locus Function
No. SNPs
studied in
locus
No. SNPs
p,0.01 SNP
Fisher Genotypic
test p-value
Log Additive
model Genotypic
test p-value
Global haplotype
simulated
p-value**
1 LOC127602 flanking 39 UTR 11 1 rs1871570 0.009 0.009 0.079
7 NOD1 UTR 9 1 rs2906766 0.004 0.009 0.42
7 PLXNA4B intron 15 1 rs11773117 0.002 0.017 0.34
17 METT10D 59 UTR 17 1 rs4790335 0.003 0.64 0.53
The SNPs (all Tag-SNPs) from the 4 loci that showed possible association with AMD in the Mayo subjects are listed in this table.
*
*Genotype distributions are provided in Table S3.
**Global haplotype refers to the 3-SNP haplotype score across the entire gene using all SNPs.
doi:10.1371/journal.pone.0003813.t003
Table 4. Results of genotyping 6 SNPs from the 3 loci in Table 3 with possible association with AMD in the Mayo subjects on 1,598
(1,280 cases and 318 controls) AREDS subjects.*
Chromosome Locus SNP Function Mayo Samples AREDS Samples (Replication subjects)
Fisher Genotypic
test p-value
Log Additive
model Genotypic
test p-value
Fisher Genotypic
test p-value
Log Additive
Model Genotypic
test p-value
1 LOC127602 rs1871570 intron 0.009 0.009 0.61 0.49
1 LOC127602 rs12038394 intron 0.07 0.02 0.93 0.7
7 NOD1 rs2906766 59 untranslated region 0.004 0.009 0.38 0.23
7 PLXNA4B rs1499300 intron 0.02 0.01 0.16 0.77
7 PLXNA4B rs2341823 intron 0.12 0.04 0.005 0.01
7 PLXNA4B rs11773117 intron 0.002 0.01 0.34 0.52
*Genotype distributions are provided in Table S4. Note that METT10D (Table 3) was not genotyped because the log-additive model did not support true association.
doi:10.1371/journal.pone.0003813.t004
GWAS Replication
PLoS ONE | www.plosone.org 5 November 2008 | Volume 3 | Issue 11 | e3813polymorphism due to the fast forms probable involvement in other
diseases including renal transplant survival, Chagas disease cardio-
myopathy, and type II mesangiocapillary glomerulonephritis [31–
33]. Variation in C3 is thus the third complement locus strongly
implicated in the risk of AMD, in addition to CFH and C2/BF.
An additional focus of this study was to better understand how
strategies for selecting SNPs in a GWAS for subsequent replication
would perform empirically. With the recent advancements of
genotyping technology, GWASs are being completed in record
numbers. The current dilemma faced by researchers is how to
determine which SNPs to follow-up in replication and subsequent
functional studies. Very low p-values, compared to the overall
distribution of p-values in a GWAS, are commonly used to select
SNPs for subsequent replication. This strategy would have
captured the CFH and LOC387715/HTRA1 loci which had the
two highest p-values in the study, 1.4610
211 and 2.5610
27
respectively. However, the p-values for the C2/BF and C3 loci
were similar to p-values for other loci which failed to replicate
(Table S1) in the AREDS GWAS. Thus, selection of only
extremely significant p-values from small genome-wide association
studies may not be an effective strategy for identification of disease
loci and may miss less significant but replicable associations.
Another commonly used strategy is to apply a log-additive
genetic model (trend test) to the genotype distributions for ranking
association with disease [7]. Since only allele-association (x
2)p -
values were available to us at the start of this project and we based
our selection of loci for replication on this metric, we can make
post-hoc comparisons to the genotype distributions that later
became available. Relying on the log-additive model would have
been superior to x
2 tests based on allelic (262) or genotype (263)
tests for association. Table 5 shows that the non-replicated SNPs
had significantly less significant (higher) p-values (mean
P=0.1560.36) for the log-additive genotype test than did the
replicated associations (mean P=0.0000160.000016; t test,
P=2.22610
213). For example, reliance on the log-additive genetic
model test rather than the 262 allelic x
2 would have excluded 32/
56 of the non-replicated SNPs and none (0/4) of the replicated
SNPs/loci at the same level of significance (P,10
24).
As noted in the introduction, clustering of SNPs significantly
associated with case-control status is thought to provide support for
the association.While thisstudywasongoing,we observed clustering
of SNPs associated with AMD in toll-like receptor (TLR) loci [30].
The association with AMD was shown to be spurious in extensive
replication studies, demonstrating that (as expected) clustering can
arise due to linkage disequilibrium with or without true association
with disease [30]. We also observed in the present study that
clustering of SNPs was not useful in selection of loci for replication
(TableS1).Wealsoarenot convinced that clusteringprotectsagainst
genotyping error, because copy number variation could extent
across a locus with multiple SNPs associated with disease.
The AREDS subjects came from 11 different clinics represent-
ing different regions of the USA [26]. In addition to including
subjects of different ethnicities, we expected considerable genetic
variation between the different clinical sites. Our replication
strategy used tag-SNPs selected based on linkage disequilibrium,
because variation in linkage disequibrium between SNPs in
different populations is a cause of failed replication in GWASs
[11,28]. In addition to genotyping the 46 AREDS loci themselves,
we used tag-SNPs to account for differences in linkage disequi-
librium between the AREDS subjects and the Mayo subjects. Even
though we have preliminary data showing the existence of
population substructure within the AREDS subjects (data not
shown), none of the 225 tag-SNPs were clearly associated with
AMD. Even though the use of tag-SNPs would allow study of
T
a
b
l
e
5
.
S
N
P
a
n
d
l
o
c
u
s
v
a
r
i
a
b
l
e
s
f
o
r
t
h
e
5
6
s
u
c
c
e
s
s
f
u
l
l
y
g
e
n
o
t
y
p
e
d
l
o
c
i
t
h
a
t
w
e
r
e
s
t
u
d
i
e
d
f
o
r
r
e
p
l
i
c
a
t
i
o
n
o
f
t
h
e
a
s
s
o
c
i
a
t
i
o
n
w
i
t
h
A
M
D
.
*
R
e
p
l
i
c
a
t
i
o
n
S
t
a
t
u
s
A
v
e
r
a
g
e
M
i
n
o
r
A
l
l
e
l
e
F
r
e
q
u
e
n
c
y
H
W
E
p
-
v
a
l
u
e
S
N
P
C
a
l
l
R
a
t
e
d
b
G
a
P
a
l
l
e
l
i
c
p
-
v
a
l
u
e
G
e
n
e
r
a
l
m
o
d
e
l
F
i
s
h
e
r
p
-
v
a
l
u
e
A
d
d
i
t
i
v
e
m
o
d
e
l
p
-
v
a
l
u
e
M
i
n
o
r
a
l
l
e
l
e
f
r
e
q
u
e
n
c
y
i
n
c
o
n
t
r
o
l
s
f
o
r
a
d
j
a
c
e
n
t
u
p
s
t
r
e
a
m
S
N
P
H
W
E
p
-
v
a
l
u
e
f
o
r
a
d
j
a
c
e
n
t
u
p
s
t
r
e
a
m
S
N
P
d
b
G
a
P
a
l
l
e
l
e
i
c
p
-
v
a
l
u
e
f
o
r
a
d
j
a
c
e
n
t
u
p
s
t
m
S
N
P
M
i
n
o
r
a
l
l
e
l
e
f
r
e
q
u
e
n
c
y
i
n
c
o
n
t
r
o
l
s
f
o
r
a
d
j
a
c
e
n
t
d
o
w
n
s
t
r
e
a
m
S
N
P
H
W
E
p
-
v
a
l
u
e
f
o
r
a
d
j
a
c
e
n
t
d
o
w
n
s
t
r
e
a
m
S
N
P
d
b
G
a
P
p
-
v
a
l
u
e
f
o
r
a
d
j
a
c
e
n
t
d
o
w
n
s
t
r
e
a
m
S
N
P
N
u
m
b
e
r
o
f
s
i
g
n
i
f
i
c
a
n
t
S
N
P
s
w
i
t
h
i
n
2
0
k
b
o
f
A
R
E
D
S
S
N
P
N
o
t
-
r
e
p
l
i
c
a
t
e
d
0
.
1
6
3
0
.
3
2
6
0
.
9
9
8
3
.
7
8
2
E
-
0
5
1
.
5
0
0
E
-
0
4
0
.
1
5
8
0
.
2
5
6
0
.
5
4
2
0
.
2
9
5
0
.
2
6
3
0
.
5
2
0
0
.
2
4
3
0
.
5
7
1
R
e
p
l
i
c
a
t
e
d
0
.
2
7
8
0
.
2
5
7
0
.
9
9
5
7
.
7
1
8
E
-
0
6
2
.
1
2
0
E
-
0
5
1
.
0
0
3
E
-
0
5
0
.
3
0
2
0
.
4
7
9
0
.
3
3
9
0
.
2
7
8
0
.
2
8
8
0
.
1
3
5
2
.
5
0
0
*
T
h
e
i
n
d
i
v
i
d
u
a
l
d
a
t
a
p
o
i
n
t
s
f
r
o
m
e
a
c
h
l
o
c
u
s
a
r
e
p
r
e
s
e
n
t
e
d
i
n
T
a
b
l
e
S
1
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
0
3
8
1
3
.
t
0
0
5
GWAS Replication
PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3813haplotype association, there would seem to be minimal, if any
value, to including tag-SNPs during the initial phase of replication
of GWAS results given the increased cost of genotyping.
Our experience with the AREDS 100,000 SNP GWAS and
other studies suggests some simple guidelines for designing
GWASs and replication studies that would improve the ability to
efficiently detect disease associated loci [34,35]. It is generally
accepted that performing the initial GWAS using 2 or more
cohorts of sufficient size is helpful in identifying loci that might be
missed in one study. Selection of SNPs for replication should be
based upon genotype distributions between cases and controls
using appropriate statistical methods [5,7] and not on 262 tests for
allelic association, clustering of SNPs, or other features of the loci
except for having a minor allele frequency high enough to enable
adequate power in the study. Adjustment for multiple testing can
be considered and applied, although it is unclear how such
methods would perform in actual practice [36]. The threshold for
p-values to select the set of SNPs for replication should not be so
high as to exclude truly associated loci of modest effects. To
facilitate the use of public databases (e.g., dbGaP) of GWASs, the
genotype counts should be publically available. The significance
results presented should be based on genotype distributions using
both the 1 degree of freedom trend test and 2 degree of freedom
tests, rather than allelic tests.
Supporting Information
Table S1 Features of the 56 of 57 AREDS SNPs highly
associated with AMD (P,10E-04) in the AREDS 100,000 SNP
genome wide association study that were not replicated are shown
in the top section of this table. SNPs from the CFH, BF/C2 and
LOC387715/HTRA1 loci already known to be associated with
AMD and the C3 locus replicated in this study are shown in the
bottom section of this table. Abbreviations: HWE, Hardy-
Weinberg equilibrium; SNP, single nucleotide polymorphism;
AREDS, age-related eye disease study.
Found at: doi:10.1371/journal.pone.0003813.s001 (0.17 MB
DOC)
Table S2 Biological information and statistical tests of allele and
genotype association with AMD in the AREDS subjects (dbGAP
data) and Mayo subjects. The replicated SNP in C3 is highlighted.
Found at: doi:10.1371/journal.pone.0003813.s002 (0.17 MB
DOC)
Table S3 Genotype distribution for all 300 SNPs genotyped on
Mayo samples, which includes 57 AREDS SNPs, 225 tagSNPs,
and 18 non-synonymous SNPs.
Found at: doi:10.1371/journal.pone.0003813.s003 (1.85 MB
DOC)
Table S4 Genotype distribution results for 6 SNPs with
significant log-additive p-values in Mayo samples compared to
genotype distribution results for the same SNPs genotyped in
AREDS samples (replication cohort).
Found at: doi:10.1371/journal.pone.0003813.s004 (0.06 MB
DOC)
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